BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Pharmacia  Europe  EEIG  submitted  on  12  October  2000  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Dynastat,  through  the  centralised  procedure.  On  16  October  2001,  the  EMEA  was  notified  that 
following the merger of Searle with Pharmacia & Upjohn, the applicant changed to Pharmacia Europe 
EEIG.  
After agreement by the CPMP on 14-16 March 2000, this medicinal product has been referred to Part 
B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr David Lyons 
Co-Rapporteur:  Dr Lars Gramstad 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  23  September  1999.  The  Scientific 
Advice pertained to part IV of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 31 October 2000. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 16 January 
2001. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 15 
January 2001. 
During the meeting on February 2001 the CPMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 
27 February 2001. 
The company submitted the responses to the CPMP consolidated List of Questions on 16 May 
2001. 
The summary report of the inspection carried out at the manufacturing site between 23-26 April 
2001 of the Searle Barceloneta facility in Puerto Rico was issued on 21 June 2001. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  Joint  Assessment  Report  on  the  company’s 
responses to the List of Questions to all CPMP members on 3 July 2001. 
During the CPMP meeting on 24-26 July 2001, the List of Outstanding Issues to be addressed in 
writing and during an Oral Explanation was discussed and agreed by the CPMP. 
The company submitted the responses to the List of Outstanding Issues on 19 September 2001. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  Joint  Assessment  Report  on  the  company’s 
written responses to the List of Outstanding Issues to all CPMP members on 2 October 2001. 
During  the  CPMP  meeting  on  17  October  2001,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
The company, Pharmacia Europe EEIG, provided on 14 November 2001, a letter of undertaking 
on the follow-up measures to be fulfilled as requested by the CPMP. 
During  the  meeting  on  13-15  November  2001  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Dynastat on 15 November 2001. 
1/2 
EMEA 20054 
 
 
 
• 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 22 March 2002. 
2/2 
EMEA 20054 
 
 
 
 
